Karuna Therapeutics, Inc. , a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, recently announces the appointment of Will Kane as chief commercial officer (CCO), effective February 6, 2023.
“The addition of Will to our executive team represents an important step as we execute on our plan to transition Karuna to a fully integrated R&D and commercial organization,” said Bill Meury, president and chief executive officer, Karuna Therapeutics. “Will is an exceptional leader and has extensive commercial operations experience, which will be invaluable as we focus our attention on the potential approval and launch of KarXT in schizophrenia.”
“I could not be joining Karuna at a more exciting time for the company and important time for people living with schizophrenia and their friends and families,” said Will Kane. “I have been impressed with the work of the team to date, and I look forward to leading a commercial organization that may have an opportunity to truly change the treatment paradigm for one of the most debilitating serious mental health conditions.”
Mr. Kane brings more than three decades of experience in the pharmaceutical industry. He’s held senior level commercial positions at leading biopharma companies, Allergan, Pfizer, and Sepracor (now Sunovion Pharmaceuticals), and was an integral part of launching several successful brands, including CELEBREX for the treatment of arthritis, NAMZARIC for Alzheimer’s disease, VRAYLAR for the treatment of schizophrenia and bipolar disorder, and UBRELVY, the first oral calcitonin gene-related peptide (CGRP) for the acute treatment of migraine. Most recently, he was the executive vice president and chief commercial officer at BioXcel Therapeutics.
Mr. Kane holds a B.A. in Government from Connecticut College and an M.B.A. from the Wharton School at the University of Pennsylvania.
